Hiroshi Tsubamoto1, Takashi Sonoda2, Shinichi Ikuta3, Satoshi Tani4, Kayo Inoue5, Naoki Yamanaka3. 1. Department of Medical Oncology, Meiwa Hospital, Nishinomiya, Hyogo, Japan Department of Obstetrics and Gynecology, Hyogo College of Medicine, Nishinomiya, Hyogo, Japan tsuba@hyo-med.ac.jp. 2. Department of Medical Oncology, Meiwa Hospital, Nishinomiya, Hyogo, Japan. 3. Department of Surgery, Meiwa Hospital, Nishinomiya, Hyogo, Japan. 4. Department of Medical Oncology, Kohnan Hospital, Higashinada-ku, Kobe, Japan. 5. Department of Medical Oncology, Meiwa Hospital, Nishinomiya, Hyogo, Japan Department of Obstetrics and Gynecology, Hyogo College of Medicine, Nishinomiya, Hyogo, Japan.
Abstract
AIM: We evaluated the efficacy and safety of itraconazole after first-line chemotherapy in patients with metastatic biliary tract cancer (BTC). PATIENTS AND METHODS: We retrospectively reviewed data from patients with histologically-diagnosed BTC with distant metastases who had received one or more lines of chemotherapy and subsequent itraconazole chemotherapy. RESULTS: Among 28 enrolled patients, 26 (93%) received docetaxel (35 mg/m(2)), gemcitabine (1,000 mg/m(2)), and carboplatin (AUC4) on day 1 and oral itraconazole solution (400 mg) on days -2 to 2, repeated every 2 weeks. Two patients received docetaxel plus itraconazole with irinotecan. Two complete responses and 14 partial responses were observed, with a response rate of 57%. The median overall survival was 12.0 months. During 160 cycles, 21 (75%) and 17 (61%) patients had grade 3/4 neutropenia and thrombocytopenia, respectively. Two patients (7%) experienced febrile neutropenia. CONCLUSION: Combination chemotherapy with itraconazole after first-line chemotherapy is promising for patients with metastatic BTC. Copyright
AIM: We evaluated the efficacy and safety of itraconazole after first-line chemotherapy in patients with metastatic biliary tract cancer (BTC). PATIENTS AND METHODS: We retrospectively reviewed data from patients with histologically-diagnosed BTC with distant metastases who had received one or more lines of chemotherapy and subsequent itraconazole chemotherapy. RESULTS: Among 28 enrolled patients, 26 (93%) received docetaxel (35 mg/m(2)), gemcitabine (1,000 mg/m(2)), and carboplatin (AUC4) on day 1 and oral itraconazole solution (400 mg) on days -2 to 2, repeated every 2 weeks. Two patients received docetaxel plus itraconazole with irinotecan. Two complete responses and 14 partial responses were observed, with a response rate of 57%. The median overall survival was 12.0 months. During 160 cycles, 21 (75%) and 17 (61%) patients had grade 3/4 neutropenia and thrombocytopenia, respectively. Two patients (7%) experienced febrile neutropenia. CONCLUSION: Combination chemotherapy with itraconazole after first-line chemotherapy is promising for patients with metastatic BTC. Copyright